Jan. 26, 2024 - Important guidance on “acting jointly or in concert” in a proxy contest was provided by the British Columbia Securities Commission (Commission) in NorthWest Copper Corp. (December 22, 2023). The Commission declined to find a joint actor relationship between a dissident and another...
Announcement
BELLUS Health Inc. Reaches Agreement for US$2-Billion Sale to GSK
Davies is acting as counsel to BELLUS Health, Inc. in its US$2-billion sale to GSK, a global pharmaceutical company headquartered in the United Kingdom.
Based in Montréal, BELLUS Health works to better the lives of patients suffering from refractory chronic cough (RCC) that does not respond to treatment for an underlying condition or is otherwise unexplained.
The acquisition provides GSK with access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist developed by BELLUS Health. Camlipixant is currently in phase III development for the first-line treatment of adult patients with RCC. The acquisition also complements GSK’s expertise in respiratory medicines and enhances its leading R&D, manufacturing and commercialization capabilities.
The transaction is expected to close in the third quarter of 2023 or earlier.
The Davies team advising on the transaction includes Sébastien Roy, Amélie Doyon and Ryan Brun (Corporate and Public M&A); Brian Bloom and Taj Kudhail (Tax); Charles Tingley (Competition, Antitrust and Foreign Investment); Hélène Bussières (Employment, Labour and Executive Compensation); and Louis-Martin O'Neill and Faiz Lalani (Dispute Resolution).
Related
Jan. 10, 2024 - What is a spurned seller’s recourse when a buyer walks away from a deal in breach of the purchase agreement? In private M&A, the answer is reasonably straightforward: sue the buyer to close the deal or to recover damages. In public M&A, however, the answer is murky at best. The problem arises...
